About: Treatment outcomes for patients with Middle Eastern Respiratory Syndrome Coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Treatment outcomes for patients with Middle Eastern Respiratory Syndrome Coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Treatment outcomes for patients with Middle Eastern Respiratory Syndrome Coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia
Creator	Sood, Geeta Al Ghamdi, Mohammed Alsulami, Abdulmoatani Alzahrani, Ameera Ghandoora, Yasmeen Salah, Fatmah Vaidya, Dhananjay Alghamdi, Khalid Bawayan, Mayada Perl, Trish
Source	Medline; PMC
abstract	BACKGROUND: Middle Eastern Respiratory Syndrome coronavirus (MERS-CoV) is a poorly understood disease with no known treatments. We describe the clinical features and treatment outcomes of patients with laboratory confirmed MERS-CoV at a regional referral center in the Kingdom of Saudi Arabia. METHODS: In 2014, a retrospective chart review was performed on patients with a laboratory confirmed diagnosis of MERS-CoV to determine clinical and treatment characteristics associated with death. Confounding was evaluated and a multivariate logistic regression was performed to assess the independent effect of treatments administered. RESULTS: Fifty-one patients had an overall mortality of 37 %. Most patients were male (78 %) with a mean age of 54 years. Almost a quarter of the patients were healthcare workers (23.5 %) and 41 % had a known exposure to another person with MERS-CoV. Survival was associated with male gender, working as a healthcare worker, history of hypertension, vomiting on admission, elevated respiratory rate, abnormal lung exam, elevated alanine transaminase (ALT), clearance of MERS-CoV on repeat PCR polymerase chain reaction (PCR) testing, and mycophenolate mofetil treatment. Survival was reduced in the presence of coronary artery disease, hypotension, hypoxemia, CXR (chest X-ray) abnormalities, leukocytosis, creatinine >1 · 5 mg/dL, thrombocytopenia, anemia, and renal failure. In a multivariate analysis of treatments administered, severity of illness was the greatest predictor of reduced survival. CONCLUSIONS: Care for patients with MERS-CoV remains a challenge. In this retrospective cohort, interferon beta and mycophenolate mofetil treatment were predictors of increased survival in the univariate analysis. Severity of illness was the greatest predictor of reduced survival in the multivariate analysis. Larger randomized trials are needed to better evaluate the efficacy of these treatment regimens for MERS-CoV.
has issue date	2016-04-21(xsd:dateTime)
bibo:doi	10.1186/s12879-016-1492-4
bibo:pmid	27097824
has license	cc-by
sha1sum (hex)	7a7c1c991ee3905b06ca628a523f693a402cc7f1
schema:url	https://doi.org/10.1186/s12879-016-1492-4
resource representing a document's title	Treatment outcomes for patients with Middle Eastern Respiratory Syndrome Coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia
has PubMed Central identifier	PMC4839124
has PubMed identifier	27097824
schema:publication	BMC Infect Dis
resource representing a document's body	covid:7a7c1c991ee3905b06ca628a523f693a402cc7f1#body_text
is schema:about of	named entity 'patients' named entity 'male' named entity 'performed' named entity 'MERS-CoV' named entity 'regional' named entity 'assess' named entity 'Kingdom' named entity 'HEALTHCARE WORKERS' named entity 'DETERMINE' named entity 'NEEDED' named entity 'PREDICTOR' named entity 'MG%' named entity 'SEVERITY OF ILLNESS' named entity 'RETROSPECTIVE' named entity 'INCREASED' named entity 'INTERFERON BETA ' named entity 'CHART REVIEW' named entity 'UNDERSTOOD' named entity 'CONCLUSIONS' named entity 'CXR' named entity 'DESCRIBE' named entity 'CARE' named entity 'MIDDLE EASTERN RESPIRATORY SYNDROME' named entity 'MALE' named entity 'TESTING' named entity 'METHODS' named entity 'ALANINE TRANSAMINASE' named entity 'CREATININE' named entity 'UNIVARIATE ANALYSIS' named entity 'VOMITING' named entity 'TREATMENTS' named entity 'YEARS' named entity 'REGIMENS' named entity 'EXAM' named entity 'POORLY' named entity 'ELEVATED' named entity 'PERFORMED' named entity 'PERSON' named entity 'RENAL FAILURE' named entity 'ANEMIA' named entity 'ON ADMISSION' named entity 'TREATMENT' named entity 'X-RAY' named entity 'REGIONAL' named entity 'CLINICAL FEATURES' named entity 'IS A' named entity 'COHORT' named entity 'PCR' named entity 'DISEASE' named entity 'RESULTS' named entity 'REFERRAL' named entity 'ABNORMAL LUNG' named entity 'CHARACTERISTICS' named entity 'CONFIRMED DIAGNOSIS' named entity 'INDEPENDENT' named entity 'ABNORMALITIES' named entity 'REFERRAL' named entity 'PATIENTS' named entity 'LARGER' named entity 'KNOWN' named entity 'BETTER' named entity 'REDUCED' named entity 'PRESENCE OF' covid:arg/7a7c1c991ee3905b06ca628a523f693a402cc7f1 named entity 'CONFIRMED' named entity 'CORONAVIRUS' named entity 'ADMINISTERED' named entity 'RANDOMIZED TRIALS' named entity 'MIDDLE EASTERN RESPIRATORY SYNDROME' named entity 'CORONAVIRUS' named entity 'CLEARANCE' named entity 'EVALUATE'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software